Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees

Table 1 Demographic and clinical characteristics of SPAA and CCB+statin primary prevention patients

	SPAA		CCB+Statin
Characteristic	(N = 1,537)		(N = 17,910)		p-value
Age: (Years)
Mean	53.5		54.8		<.001
SD	7.6		8.5
Median	55		55
Age group: (n,%)					<.001
<50 years	412	26.8%	4,119	23.0%
50-59 years	816	53.1%	9,636	53.8%
60+ years	309	20.1%	4,155	23.2%
Gender: (n,%)
Male	900	58.6%	9,327	52.1%	<.001
Geographic Region: (n,%)					<.001
Northeast	525	34.2%	4,705	26.3%
Midwest	389	25.3%	7,314	40.8%
South	595	38.7%	5,296	29.6%
West	28	1.8%	595	3.3%
Plan Type: (n,%)					<.001
Health Maintenance Organization (HMO)	311	20.2%	6,429	35.9%
Indemnity Plan	92	6.0%	885	4.9%
Point of Service (POS)	217	14.1%	2,313	12.9%
Preferred Provider Organization (PPO)	884	57.5%	7,805	43.6%
Unknown	33	2.1%	478	2.7%
Payer Type: (n,%)					<.001
Commercial Plan	1,462	95.1%	16,121	90.0%
Medicaid	1	0.1%	158	0.9%
Medicare Risk	26	1.7%	1,086	6.1%
Self-Insured	38	2.5%	464	2.6%
Other/Unknown	10	0.7%	81	0.5%
Charlson Comorbidity Burden:
Mean	0.4		0.5		<.001
SD	0.7		0.8
Comorbid Conditions of Interest: (n,%)
Diabetes Mellitus	363	23.6%	5,242	29.3%	<.001
Dyslipidemia	1,188	77.3%	12,217	68.2%	<.001
Obesity	76	4.9%	1,063	5.9%	0.112
Peripheral Vascular Disease	35	2.3%	476	2.7%	0.371
Chronic Obstructive Pulmonary Disease	39	2.5%	638	3.6%	0.035
Number of Pre-Index Unique Prescriptions:					<.001
1-2	252	16.4%	1,847	10.3%
3-4	392	25.5%	3,646	20.4%
5-6	310	20.2%	3,682	20.6%
7+	583	37.9%	8,735	48.8%
Number of Pre-Index Other Antihypertensive Classes:					<.001
0	675	43.9%	6,771	37.8%
1	718	46.7%	9,237	51.6%
2	127	8.3%	1,693	9.5%
3+	17	1.1%	209	1.2%

ISSN: 1471-2261